A new arthritis drug might help melanoma patients , according to the medical journal Oncotarget. Melanoma is a rare form of skin cancer, but it is also one of the most deadly. Leflunomide, a drug designed to help patients with rheumatoid arthritis, triggers apoptosis in some patients. Melanoma is a condition where the body’s melanin producing cells mutate. Melanin is the pigment the body produces to help the body protect itself against damage from the sun. Rheumatoid arthritis is an autoimmune conditions where the body’s immune cells. Check the journal at SCImago Journal & Country Rank.
As with many other drugs designed to treat autoimmune conditions, leflunomide is designed to repress the immune system. One of the newest treatments for cancers has been immune therapies. These therapies are designed to repress the immune system. Although the purpose of the drug in autoimmune conditions is to keep the immune system from attacking the body, these drugs have a different role in treating cancer. They are keeping the body’s immune system from developing a resistance to the tumor. When cancer spreads, the body’s immune system correctly recognizes the tissue as part of the body. The treatment works well for many types of cancers, but there is one drawback. Patients who go into remission and achieve a cure suffer a greater risk of developing autoimmune diseases later.’ Follow Oncotarget journal on Twitter.
The discovery brings hope for thousands of melanoma patients around the world. Even though this skin cancer may not be the most common form of the disease, it is the most deadly. The new drug promises to increase the remission and cure rates for melanoma. Any improvement of the survivalibility rates is welcome news for many types of cancer patients.